Abstract 45P
Background
Pathologic complete response (pCR) is often utilized as a surrogate marker for overall survival in breast cancer. Significant differences in pCR rates are reported in many studies depending on the biological tumor profile and molecular classification. Based on our observations we hypothesize that few breast cancer patients are less likely to achieve pCR after neoadjuvant chemotherapy (NACT). The role of demographic variables in predicting pCR is still not clear. The aim of this study was to evaluate various demographic factors which could impact pCR rates.
Methods
A prospective analysis of 1246 patients with breast carcinoma who had undergone neoadjuvant chemotherapy (NACT) followed by surgery was done from June 2020 to December 2022. Demographic, surgical, and pathological data were collected on completion of therapy. Categorical variables were analyzed using χ2 or Fisher’s exact test and continuous data were analyzed using t-tests. Multiple linear regressions were used to study interactions between various demographic factors and pCR. Statistical analysis was done using SPSS v25.
Results
A total of 1324 patients were offered NACT, of which 1246 (94.1%) who underwent resection post-NACT were included in the analysis. Overall, 275 (22.1%) patients had pCR. 39 (14.2%) in ER+/HER2- group, 131 (47.6%) in HER2+ group; and 105 (38.2%) in ER-/HER2- group had pCR. Univariate analysis showed significant association between age <50 years, low body-mass index, and ability to achieve pCR. However, women with obesity had higher odds of residual disease (OR = 0.191 [0.029-1.157]; p=0.076). The results were consistent even after controlling for confounding variables such as grade, receptor status, and clinical T and N stages.
Conclusions
Younger age can predict a pCR and is an independent prognostic factor for locoregional recurrence in locally advanced breast cancer patients after NACT. Obesity is a risk factor for failure to achieve PCR in women undergoing NACT. The contrary was observed in non-obese patients as they had higher odds of achieving PCR. Studies with larger groups are needed to validate this observation. Further studies evaluating the role of BMI in drug resistance would be valuable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract